Express News | D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

BenzingaJan 13 08:27 ET

Humacyte Provides Update on Commerical Launch, Pricing of Symvess

TipRanksJan 13 08:26 ET

Humacyte Analyst Ratings

BenzingaJan 13 08:23 ET · Ratings

Express News | Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (Acellular Tissue Engineered Vessel-Tyod) for Extremity Vascular Trauma

ReutersJan 13 08:00 ET

Humacyte Provides Update on Commercial Launch and Pricing of Symvess (Acellular Tissue Engineered Vessel-tyod) for Extremity Vascular Trauma

HumacyteJan 13 00:00 ET

Individual Investors Who Own 46% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week

Simply Wall StDec 25, 2024 06:44 ET